Compare TBPH & BW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TBPH | BW |
|---|---|---|
| Founded | 2013 | 1867 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Building Products |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 919.9M |
| IPO Year | 2013 | N/A |
| Metric | TBPH | BW |
|---|---|---|
| Price | $13.86 | $14.12 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $18.50 | $7.00 |
| AVG Volume (30 Days) | 782.6K | ★ 4.7M |
| Earning Date | 05-07-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.88 | N/A |
| Revenue | ★ $15,386,000.00 | N/A |
| Revenue This Year | $70.90 | $16.59 |
| Revenue Next Year | N/A | $14.08 |
| P/E Ratio | $15.75 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.90 | $0.22 |
| 52 Week High | $21.03 | $15.29 |
| Indicator | TBPH | BW |
|---|---|---|
| Relative Strength Index (RSI) | 27.74 | 61.48 |
| Support Level | $13.41 | $8.03 |
| Resistance Level | $14.76 | N/A |
| Average True Range (ATR) | 0.58 | 1.45 |
| MACD | -0.08 | 0.19 |
| Stochastic Oscillator | 11.29 | 84.60 |
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Babcock & Wilcox Enterprises Inc is a power generation equipment supplier and servicing company that operates in three segments: B&W Renewable, B&W Environmental, and B&W Thermal. B&W Thermal, focuses on steam generation products and solutions for plants in the power generation, oil, and gas, and industrial sectors, generates the majority of the company's revenue. B&W Renewable focuses on sustainable power and heat generation while B&W Environmental focuses on emissions control. The company's customer base spans the industrial, electrical utility, and municipal industries located predominantly in the United States, Canada, Denmark, the United Kingdom, and other regions. Business in the U.S. contributes the vast majority of its revenue.